Found: 6
Select item for more details and to access through your institution.
Response to the letter to the editor regarding our article 'statistical methodology for highly variable compounds: A novel design approach for the ofatumumab phase 2 bioequivalence study' https://doi.org/10.1002/pst.2233.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1368, doi. 10.1002/pst.2254
- By:
- Publication type:
- Article
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1357, doi. 10.1002/pst.2233
- By:
- Publication type:
- Article
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1576, doi. 10.1177/13524585221079731
- By:
- Publication type:
- Article
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 3, p. 283, doi. 10.1007/s40263-021-00895-w
- By:
- Publication type:
- Article
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 1, p. 303, doi. 10.1007/s40120-022-00427-8
- By:
- Publication type:
- Article
(DXT02) Early Effect of Ofatumumab on B-Cell Counts and Magnetic Resonance Imaging Activity in Relapsing Multiple Sclerosis Patients: Results from the APLIOS Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 16
- By:
- Publication type:
- Article